NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP
Shreeram Aradhye/LinkedIn
Aug 13, 2025, 10:08

Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP

Shreeram Aradhye, President, Development and Chief Medical Officer at Novartis, shared an announcement on LinkedIn:

”Primary immune thrombocytopenia (ITP) is a rare autoimmune blood disorder characterized by low platelet counts leading to an increased risk of bleeding, bruising and chronic fatigue. For many people living with ITP, chronic treatment can disrupt their daily life due to the burden of regular dosing, dose adjustments and side effects.

Today, we announced positive top-line results from our investigational treatment in primary ITP.

This marks our second positive data readout for this investigational asset as yesterday we announced positive Phase III results in Sjögren’s disease – reinforcing our efforts to addressing areas of high unmet needs across B-cell driven diseases.

With over two decades of experience advancing care in ITP, this milestone underscores our commitment to continuing to innovate with the aim of finding new and meaningful ways to improve patient outcomes.

I would like to extend my gratitude to the patients, families, and teams who made this possible as we reimagine medicine together.”

Read more about Shreeram Aradhye’s announcement here.

Shreeram Aradhye: Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP

Stay updated on the latest breakthroughs in drug development with Hemostasis Today.

bleeding bruising chronic fatigue Headlines Health Hematology Hemostasis Today Ianalumab ITP Medicine Novartis Primary immune thrombocytopenia Shreeram Aradhye
NewsFeed